Navigation Links
Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
Date:5/31/2008

- Poster Presented at ASCO Annual Meeting -

SOUTH SAN FRANCISCO, Calif. and CHICAGO, May 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today presented preliminary safety and efficacy data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone, the standard of care for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC). Results demonstrated that picoplatin can be safely administered with full doses of docetaxel. In addition, the prostate specific antigen (PSA) response rate was 69 percent in 26 patients evaluable for PSA.

The Company presented the Phase 2 data (abstract #5153) in the General Poster Session during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations.

"The promising results of this Phase 2 trial in HRPC support further development of picoplatin in the treatment of prostate cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "A prospective randomized trial is under consideration. The combination of picoplatin with a taxane could be further evaluated in other tumor types, such as ovarian cancer and non-small cell lung cancer."

Phase 2 HRPC Study Preliminary Results

In the ongoing Phase 2 trial, the efficacy and safety of intravenous picoplatin (120 mg/m squared) administered every 21 days in combination with full-dose docetaxel (75 mg/m squared) with dail
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
2. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
3. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
10. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
11. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2008)...s innovation leadership and long-term commitment t...Nov. 24 Schering-Plough ...al update on boceprevir, its lead investigational ...hase III development. The company believes bocepr...best-in-class protease inhibitor for treating chro...
(Date:11/24/2008)...v. 24 Schering-Plough Co...denant, its novel and selective adenosine2a recept... II dose-finding trial in patients suffering from ...g motor fluctuations and abnormal involuntary move...nted today at the company,s 2008 R&D Update me...
(Date:11/24/2008)...Nov. 24 GeneThera, Inc.,...gin offering its Real Time,PCR test for Johne,s d..., GeneThera is set to begin offering its Jo...of 2009. According to GeneThera Chairman, Dr. Ton... real time PCR test for Johne,s disease,called H...
(Date:11/24/2008).... 24 Medarex, Inc. (Nas...hase 1b clinical trial for MDX-1106 (ONO-4538: dev...fully human anti-PD-1 antibody for the treatment o... pathway may play an important role in tumor evasi...lso promote the persistence of certain chronic vir...
Breaking Medicine Technology:Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 2Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 3Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 4Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 1Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 2Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 3New class of drug offers hope to treatment resistant AIDS patients 777 1New class of drug offers hope to treatment resistant AIDS patients 777 2New class of drug offers hope to treatment resistant AIDS patients 777 3Dendreon Secures 24130 Million Committed Equity Financing Facility 1236 1Dendreon Secures 24130 Million Committed Equity Financing Facility 1236 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 1Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 3
... HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGeni...n, Chief Scientific Officer will,present an update...using the Company,s proprietary synDNA(TM) technol... in Malaga, Spain between May 23,and May 25., Dr. ...ts of,synDNA(TM) based vaccines in mice, rabbits a...
... EVANSTON, Ill.--(BUSINESS WIRE)--May 23, 2007 - N...ed today results of its,pivotal Phase III trauma t...oxygen-carrying red blood cell substitute. The,tri...he treatment,of life-threatening red blood cell lo...s are not available, not for use,interchangeably w...
Other Medicine Technology:CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 3Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 4Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 5Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 6Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 7Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 8
(Date:12/1/2008)...alysis of the National Cancer Institute,s cancer r...r women experience delayed or incomplete radiation...d that this suboptimal care can lead to worse outc... Medical College and colleagues found that among a...breast cancer registry patients aged 65 and older,...
(Date:12/1/2008)...D, Mass., Dec. 1 MassMutual Retire...ts to support its increasing nonprofit business. N...mpared to last year. , , Dan Darby joined ...alist for the Western region. He reports to M. Pal... market, for MassMutual,s Retirement Services Divi...
(Date:12/1/2008)...f., Dec. 1 Senetek PLC,...ny engaged in the,development of technologies tha...today that Dynamics Group AG, specialists in the f...agement and research with offices in Zurich,Bern... Company. , The Research Report, available ...
(Date:12/1/2008)...ing, steroids effective against plantar fasciitis...HealthDay News) -- Italian researchers say they,ve...nt for the painful foot condition known as plantar...ing" and steroid injections guided by ultrasound, ...ercent success rate in tackling a condition that a...
Breaking Medicine News(10 mins):Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3
...man holds the hand of a little boy, looking at a r...e area, which was in wreck two years ago, washed a...am village is exuding life now. Along the innocent...h of Chennai, India, new casurina saplings are kne...
...round the corner and this is the time to make new ...7 ?// Health watchers suggest- give yourself ...and food intake the whole year-round. Limiting...very important step, if you want to keep your hear...
...t Mayo Clinic have successfully isolated nanoparti...d have isolated proteins, RNA and DNA that appear ..., which appear in the December issue of the Journa...ficant because it is one step closer in solving th...
...Research Service (ARS) scientists have reported th...s of wheat have been found to produce flour with 2...ard J. Souza, research leader of the ARS Soft Whea...io and colleagues Mary J. Guitteri and Karen M. Pe...
Other Medicine News:Health News:Tsunami-Hit Coastal Regions Needs More Relief 2Health News:Gift Yourself A Healthy Heart 2Health News:Link Between Nanoparticles and Kidney Stones 2Health News:Link Between Nanoparticles and Kidney Stones 3
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL.
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatinine in serum. Fixed Time Reaction measured at 540 nm. Linearity: 25 mg/dl. Express Kit with Ready-to-Use Liquid.
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.
Medicine Products: